Device sales, including AirSense 10 and AirSense 11, experienced double-digit growth ... potentially redefining market standards for CPAP masks. ResMed also collaborated with Apple Vision Pro ...

CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea, according to a landmark meta-analysis supported by Resmed and published in The Lancet Respiratory Medicine ...

Resmed (NYSE: RMD) announced today that it began a comprehensive brand evolution to unify its brand portfolio.

ResMed has launched a rebrand to unify its portfolio and reflect its increasing direct-to-consumer engagement.

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed ... up 11% year over year.

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD ... has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The company’s last ...

The communication emphasizes consumer engagement and destigmatizing CPAP therapy ... SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology ...

“For people with OSA, using CPAP versus not using CPAP can literally be a matter of life or death,” said Carlos Nunez, M.D., Resmed’s Chief Medical Officer. “Decades of research have shown CPAP can ...

Largest ever meta-analysis on the long-term benefits of CPAP therapy, published in The Lancet Respiratory Medicine, found that in people with sleep apnea, CPAP therapy lowered the overall chance of dy ...

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX ... For 35 years, Resmed has pioneered innovations in respiratory therapy, including CPAP therapy and digital health solutions. The ...